Classifications

• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
  • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
  • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
  • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
  • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
  • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
• • G—PHYSICS
  • G01—MEASURING; TESTING
  • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
  • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
  • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
  • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
  • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
  • G01N33/6887—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from muscle, cartilage or connective tissue
• • G—PHYSICS
  • G01—MEASURING; TESTING
  • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
  • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
  • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
  • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
  • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
  • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
  • G01N33/54306—Solid-phase reaction mechanisms
• • G—PHYSICS
  • G01—MEASURING; TESTING
  • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
  • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
  • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
  • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
  • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
  • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
• • G—PHYSICS
  • G01—MEASURING; TESTING
  • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
  • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
  • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
  • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
  • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
  • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
  • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
• • G—PHYSICS
  • G01—MEASURING; TESTING
  • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
  • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
  • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
  • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
  • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
• • G—PHYSICS
  • G01—MEASURING; TESTING
  • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
  • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
  • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
  • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
  • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
  • G01N2333/4701—Details
  • G01N2333/4712—Muscle proteins, e.g. myosin, actin, protein
• • G—PHYSICS
  • G01—MEASURING; TESTING
  • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
  • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
  • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
  • G01N2333/575—Hormones
  • G01N2333/58—Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Brain natriuretic peptide [BNP, proBNP]; Cardionatrin; Cardiodilatin
• • G—PHYSICS
  • G01—MEASURING; TESTING
  • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
  • G01N2800/00—Detection or diagnosis of diseases
  • G01N2800/28—Neurological disorders
  • G01N2800/2871—Cerebrovascular disorders, e.g. stroke, cerebral infarct, cerebral haemorrhage, transient ischemic event
• • G—PHYSICS
  • G01—MEASURING; TESTING
  • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
  • G01N2800/00—Detection or diagnosis of diseases
  • G01N2800/32—Cardiovascular disorders
• • G—PHYSICS
  • G01—MEASURING; TESTING
  • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
  • G01N2800/00—Detection or diagnosis of diseases
  • G01N2800/32—Cardiovascular disorders
  • G01N2800/326—Arrhythmias, e.g. ventricular fibrillation, tachycardia, atrioventricular block, torsade de pointes

Definitions

• TOAST criteria dissect causes of stroke into atherothrombotic (atherosclerosis of large vessels), cardioembolic, lacunar (involving small vessels) and undetermined (Adams H. P. et al).
• atherothrombotic atherothrombotic of large vessels
• cardioembolic cardioembolic
• lacunar involving small vessels
• undetermined Adams H. P. et al
• carotid and transcranial ultrasound are required as well as echocardiography and an electrocardiogram (Rodriguez-Yanez et al, Disease Markers 2009: 26: 189-195).
• Cardiac troponins T and I are the preferred biomarkers for the diagnosis of acute myocardial infarction (Anderson J L, ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-Elevation myocardial infarction. J Am Coll Cardiol. 2007; 50(7):e1-e157). It has been recognized that elevated troponin levels may be detected in several non-acute chronic disease states, including coronary artery disease, heart failure, and chronic kidney disease (see e.g. Omland et al., N Engl J Med. 2009; 361(26):2538-2547). Troponins T and I are also been shown to be detectable in individuals from the general population (see e.g. Wallace et al., Prevalence and determinants of troponin T elevation in the general population. Circulation. 2006; 113(16):1958-1965).
• the present disclosure relates to a method for early differentiating whether a subject suffers from cardioembolic stroke or from non-cardioembolic ischemic stroke.
• the method is based on the determination of the amount of a cardiac Troponin in a sample from a subject suffering from ischemic stroke obtained not more than 24 hours after the onset of symptoms of ischemic stroke.
• the present disclosure relates to a method for diagnosing atrial fibrillation in a subject.
• kits and devices adapted to carry out the method of the present disclosure are kits and devices adapted to carry out the method of the present disclosure.
• the present disclosure also relates to a system for early differentiating whether a subject suffers from cardioembolic stroke or from non-cardioembolic ischemic stroke and for diagnosing atrial fibrillation.
• the present disclosure relates to reagents and kits used in performing the methods disclosed herein.
• cardiac Troponins in patients with cardioembolic stroke are detectable already at the onset of cardioembolic stroke.
• the increase of the level of cardiac Troponins is not caused by the stroke event.
• the studies of the present disclosure suggest that the levels of cardiac troponins are already increased before the onset of stroke symptoms. Therefore, the determination of cardiac Troponins allows for an early differentiation between cardioembolic ischemic stroke and non-cardioembolic ischemic stroke in the subject. This is advantageous since the early assessment of the cause of stroke is crucial in order to sufficiently treat a subject suffering from stroke, in particular a subject suffering from cardioembolic stroke.
• strokes due to cardioembolism are in general severe and prone to early recurrence
• the present disclosure method for early differentiating whether a subject suffers from cardioembolic stroke or from non-cardioembolic ischemic stroke comprising
• the present disclosure in particular, relates to a method for early differentiating whether a subject suffers from cardioembolic stroke or from non-cardioembolic ischemic stroke, comprising
• a subject suffers from cardioembolic ischmemic stroke or from non-cardioembolic ischemic stroke by carrying out the further step of c) diagnosing whether a subject suffers from cardioembolic ischemic stroke or from non-cardioembolic ischemic stroke, based on the results of the comparison carried out in step b).
• step a) further comprises the determination of the amount of a natriuretic peptide in the sample from the subject obtained immediately after the onset of ischemic stroke.
• the determined amount of the natriuretic peptide is compared in step b) to a reference amount for a natriuretic peptide.
• the present disclosure also relates to a method for early differentiating whether a subject suffers from cardioembolic stroke or from non-cardioembolic ischemic stroke, comprising
• the method of the present disclosure may include, is an ex vivo method. Moreover, it may comprise steps in addition to those explicitly mentioned above. For example, further steps may relate to sample pre-treatments or evaluation of the results obtained by the method.
• the method may be carried out manually or assisted by automation.
• step (a) and/or (b) may in total or in part be assisted by automation, e.g., by a suitable robotic and sensory equipment for the determination in step (a) or a computer-implemented comparison and/or differentiation based on said comparison in step (b).
• the present disclosure also preferably relates to a system for early differentiating whether a subject suffers from cardioembolic ischemic stroke or from non-cardioembolic ischemic stroke, comprising
• the term “differentiating” as used herein means to distinguish between cardioembolic stroke and non-cardioembolic stroke in a patient suffering from ischemic stroke.
• the term as used herein preferably, includes differentially diagnosing cardioembolic ischemic stroke and non-cardioembolic ischemic stroke in a subject. As will be understood by those skilled in the art, such an assessment is usually not intended to be correct for 100% of the subjects to be differentially diagnosed. The term, however, requires that a statistically significant portion of subjects can be correctly diagnosed. Whether a diagnosis/differentiation is correct can be confirmed by methods well known in the art.
• whether a portion is statistically significant can be determined without further ado by the person skilled in the art using various well known statistic evaluation tools, e.g., determination of confidence intervals, p-value determination, Student's t-test, Mann-Whitney test etc. Details are found in Dowdy and Wearden, Statistics for Research, John Wiley & Sons, New York 1983.
• Preferred confidence intervals are at least 90%, at least 95%, at least 97%, at least 98% or at least 99%.
• the p-values are, preferably, 0.1, 0.05, 0.01, 0.005, or 0.0001.
• subject as used herein relates to animals, preferably mammals, and, more preferably, humans.
• the subject does or not suffer from acute infections.
• the subject does not suffer from acute coronary syndrome and/or from chronic renal failure.
• the subject in the context with the aforementioned method shall have normal kidney function.
• the subject is, preferably, a subject presenting to an emergency unit.
• ischemic stroke (herein also referred to as “stroke”) is well known by the skilled person (see e.g. Adams et al., Guidelines for the Early Management of Adults With Ischemic Stroke, A Guideline From the American Heart Association/American Stroke Association Stroke Council, Clinical Cardiology Council, Cardiovascular Radiology and Intervention Council, and the Atherosclerotic Peripheral Vascular Disease and Quality of Care Outcomes in Research Interdisciplinary Working Groups in Stroke. 2007; 38:1655; or Stroke Genetics, edited by Hugh S.
• Ischemic stroke is caused by reduced blood flow to the brain or parts thereof which leads to a reduced delivery (undersupply) of oxygen to brain cells.
• Ischemic stroke may be characterized by tissue anemia caused by obstruction of the inflow of arterial blood. It may lead to irreversible tissue damage due to brain cell death.
• ischemic stroke There are various classification systems for ischemic stroke.
• the Oxford Community Stroke Project classification also known as the Bamford or Oxford classification
• OCSP Oxford Community Stroke Project classification
• TACI total anterior circulation infarct
• PACI partial anterior circulation infarct
• LACI lacunar infarct
• POCI posterior circulation infarct
• the so called TOAST criteria are applied herein.
• TOAST criteria see e.g. Donnan G A, Fisher M, Macleod M, Davis S M (May 2008). “Stroke”. Lancet 371 (9624): 1612-23 or “Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment”. Stroke 24 (1): 35-41., both of which are herein incorporated by reference with respect to the entire disclosure content.
• the TOAST (Trial of Org 10172 in Acute Stroke Treatment) classification is based on clinical symptoms as well as results of further investigations; on this basis, a stroke is classified as being due to (1) embolism of cardiac origin (cardioembolic stroke) (2) thrombosis or embolism due to atherosclerosis of a large artery (large artery stenosis, atherothrombotic stroke), (3) occlusion of a small blood vessel (lacunar stroke) or (4) undetermined cause (two possible causes: no cause identified, or incomplete investigation).
• preferred non-cardioembolic ischemic strokes are atherothrombotic stroke (see 2) and lacunar stroke (see 3).
• stroke symptoms include sudden numbness or weakness of face, arm or leg, especially on one side of the body, sudden confusion, trouble speaking or understanding, sudden trouble seeing in one or both eyes, and sudden trouble walking, dizziness, loss of balance or coordination.
• sample refers to a sample of a body fluid, to a sample of separated cells or to a sample from a tissue or an organ.
• Samples of body fluids can be obtained by well known techniques and include, preferably, samples of blood, plasma, serum, or urine, more preferably, samples of blood, plasma or serum.
• Tissue or organ samples may be obtained from any tissue or organ by, e.g., biopsy.
• Separated cells may be obtained from the body fluids or the tissues or organs by separating techniques such as centrifugation or cell sorting.
• cell-, tissue- or organ samples are obtained from those cells, tissues or organs which express or produce the peptides referred to herein.
• the sample to be tested in the context of the method of the present disclosure shall have been obtained immediately after the onset of symptoms of stroke (as well as the reference sample).
• a sample is deemed to have been obtained immediately after the onset of symptoms of stroke if it has been obtained from said subject not more than 24 hours, in particular not more than 12 hours after the onset of symptoms of stroke. More preferably, a sample is deemed to have been obtained immediately after the onset of symptoms of stroke if it has been obtained from said subject not more than 6 hours, and even more preferably not more than 3 hours after the onset of symptoms of ischemic stroke. Further envisaged is that the sample has been obtained not more than one or two hours after the onset of stroke symptoms.
• cardiac Troponin refers to all Troponin isoforms expressed in cells of the heart and, preferably, the subendocardial cells. These isoforms are well characterized in the art as described, e.g., in Anderson 1995, Circulation Research, vol. 76, no. 4: 681-686 and Ferrieres 1998, Clinical Chemistry, 44: 487-493.
• cardiac Troponin refers to Troponin T and/or Troponin I, and, most preferably, to Troponin T. It is to be understood that isoforms of Troponins may be determined in the method of the present disclosure together, i.e. simultaneously or sequentially, or individually, i.e. without determining the other isoform at all. Amino acid sequences for human Troponin T and human Troponin I are disclosed in Anderson, loc cit and Ferrieres 1998, Clinical Chemistry, 44: 487-493.
• cardiac Troponin encompasses also variants of the aforementioned specific Troponins, i.e., preferably, of Troponin I, and more preferably, of Troponin T. Such variants have at least the same essential biological and immunological properties as the specific cardiac Troponins. In particular, they share the same essential biological and immunological properties if they are detectable by the same specific assays referred to in this specification, e.g., by ELISA Assays using polyclonal or monoclonal antibodies specifically recognizing the said cardiac Troponins.
• a variant as referred to in accordance with the present disclosure shall have an amino acid sequence which differs due to at least one amino acid substitution, deletion and/or addition wherein the amino acid sequence of the variant is still, preferably, at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 85%, at least about 90%, at least about 92%, at least about 95%, at least about 97%, at least about 98%, or at least about 99% identical with the amino sequence of the specific Troponin.
• the degree of identity is to be determined by comparing two optimally aligned sequences over a comparison window, where the fragment of amino acid sequence in the comparison window may comprise additions or deletions (e.g., gaps or overhangs) as compared to the reference sequence (which does not comprise additions or deletions) for optimal alignment.
• the percentage is calculated by determining the number of positions at which the identical amino acid residue occurs in both sequences to yield the number of matched positions, dividing the number of matched positions by the total number of positions in the window of comparison and multiplying the result by 100 to yield the percentage of sequence identity.
• Optimal alignment of sequences for comparison may be conducted by the local homology algorithm of Smith and Waterman Add. APL. Math.
• GAP Garnier et al. (1981), by the homology alignment algorithm of Needleman and Wunsch J. Mol. Biol. 48:443 (1970), by the search for similarity method of Pearson and Lipman Proc. Natl. Acad. Sci. (USA) 85: 2444 (1988), by computerized implementations of these algorithms (GAP, BESTFIT, BLAST, PASTA, and TFASTA in the Wisconsin Genetics Software Package, Genetics Computer Group (GCG), 575 Science Dr., Madison, Wis.), or by visual inspection. Given that two sequences have been identified for comparison, GAP and BESTFIT are preferably employed to determine their optimal alignment and, thus, the degree of identity. Preferably, the default values of 5.00 for gap weight and 0.30 for gap weight length are used.
• Variants may be allelic variants or any other species specific homologs, paralogs, or orthologs.
• the variants referred to herein include fragments of the specific cardiac Troponins or the aforementioned types of variants as long as these fragments have the essential immunological and biological properties as referred to above.
• the cardiac troponin variants have immunological properties (i.e. epitope composition) comparable to those of human troponin T or troponin I.
• the variants shall be recognizable by the aforementioned means or ligands used for determination of the concentration of the cardiac troponins.
• the variants shall be recognizable by the aforementioned means or ligands used for determination of the concentration of the cardiac troponins.
• Such fragments may be, e.g., degradation products of the Troponins.
• variants which differ due to posttranslational modifications such as phosphorylation or myristylation.
• the biological property of troponin I and its variant is the ability to inhibit actomyosin ATPase or to inhibit angiogenesis in vivo and in vitro, which may e.g. be detected based on the assay described by Moses et al. 1999 PNAS USA 96 (6): 2645-2650).
• the biological property of troponin T and its variant is the ability to form a complex with troponin C and I, to bind calcium ions or to bind to tropomyosin, preferably if present as a complex of troponin C, I and T or a complex formed by troponin C, troponin I and a variant of troponin T. It is known that low concentrations of circulating cardiac troponin may be detected in subjects at various conditions, but further studies are required to understand their respective role and rate (Masson et al., Curr Heart Fail Rep (2010) 7:15-21).
• natriuretic peptide comprises Atrial Natriuretic Peptide (ANP)-type and Brain Natriuretic Peptide (BNP)-type peptides and variants thereof having the same predictive potential.
• Natriuretic peptides according to the present disclosure comprise ANP-type and BNP-type peptides and variants thereof (see e.g. Bonow, 1996, Circulation 93: 1946-1950).
• ANP-type peptides comprise pre-proANP, proANP, NT-proANP, and ANP.
• BNP-type peptides comprise pre-proBNP, proBNP, NT-proBNP, and BNP.
• the pre-pro peptide (134 amino acids in the case of pre-proBNP) comprises a short signal peptide, which is enzymatically cleaved off to release the pro peptide (108 amino acids in the case of proBNP).
• the pro peptide is further cleaved into an N-terminal pro peptide (NT-pro peptide, 76 amino acids in case of NT-proBNP) and the active hormone (32 amino acids in the case of BNP, 28 amino acids in the case of ANP).
• NT-pro peptide 76 amino acids in case of NT-proBNP
• the active hormone 32 amino acids in the case of BNP, 28 amino acids in the case of ANP.
• natriuretic peptides according to the present disclosure are NT-proANP, ANP, and, more preferably, NT-proBNP, BNP, and variants thereof.
• ANP and BNP are the active hormones and have a shorter half-life than their respective inactive counterparts, NT-proANP and NT-proBNP.
• BNP is metabolized in the blood, whereas NT-proBNP circulates in the blood as an intact molecule and as such is eliminated renally.
• the in-vivo half-life of NT-proBNP is 120 min longer than that of BNP, which is 20 min (Smith 2000, J. Endocrinol. 167: 239-46.).
• Preanalytics are more robust with NT-proBNP allowing easy transportation of the sample to a central laboratory (Mueller 2004, Clin Chem Lab Med 42: 942-4.).
• natriuretic peptides are NT-proBNP or variants thereof.
• the human NT-proBNP is a polypeptide comprising, preferably, 76 amino acids in length corresponding to the N-terminal portion of the human NT-proBNP molecule.
• the structure of the human BNP and NT-proBNP has been described already in detail in the prior art, e.g., WO 02/089657, WO 02/083913 or Bonow loc. cit.
• human NT-proBNP as used herein is human NT-proBNP as disclosed in EP 0 648 228 B1.
• the NT-proBNP referred to in accordance with the present disclosure further encompasses allelic and other variants of said specific sequence for human NT-proBNP discussed above.
• variant polypeptides which are on the amino acid level preferably, at least 50%, 60%, 70%, 80%, 85%, 90%, 92%, 95%, 97%, 98%, or 99% identical to human NT-proBNP, preferably over the entire length of human NT-proBNP.
• the degree of identity between two amino acid sequences can be determined by algorithms well known in the art.
• the degree of identity is to be determined by comparing two optimally aligned sequences over a comparison window, where the fragment of amino acid sequence in the comparison window may comprise additions or deletions (e.g., gaps or overhangs) as compared to the reference sequence (which does not comprise additions or deletions) for optimal alignment.
• the percentage is calculated by determining the number of positions at which the identical amino acid residue occurs in both sequences to yield the number of matched positions, dividing the number of matched positions by the total number of positions in the window of comparison and multiplying the result by 100 to yield the percentage of sequence identity.
• Optimal alignment of sequences for comparison may be conducted by the local homology algorithm of Smith and Waterman Add. APL. Math.
• GAP Garnier et al. (1981), by the homology alignment algorithm of Needleman and Wunsch J. Mol. Biol. 48:443 (1970), by the search for similarity method of Pearson and Lipman Proc. Natl. Acad. Sci. (USA) 85: 2444 (1988), by computerized implementations of these algorithms (GAP, BESTFIT, BLAST, PASTA, and TFASTA in the Wisconsin Genetics Software Package, Genetics Computer Group (GCG), 575 Science Dr., Madison, Wis.), or by visual inspection. Given that two sequences have been identified for comparison, GAP and BESTFIT are preferably employed to determine their optimal alignment and, thus, the degree of identity. Preferably, the default values of 5.00 for gap weight and 0.30 for gap weight length are used.
• Variants referred to above may be allelic variants or any other species specific homologs, paralogs, or orthologs. Substantially similar and also envisaged are proteolytic degradation products which are still recognized by the diagnostic means or by ligands directed against the respective full-length peptide. Also encompassed are variant polypeptides having amino acid deletions, substitutions, and/or additions compared to the amino acid sequence of human NT-proBNP as long as the said polypeptides have NT-proBNP properties.
• NT-proBNP properties as referred to herein are immunological and/or biological properties.
• the NT-proBNP variants have immunological properties (i.e. epitope composition) comparable to those of human NT-proBNP.
• the variants shall be recognizable by the aforementioned means or ligands used for determination of the amount of the natriuretic peptides.
• Biological and/or immunological NT-proBNP properties can be detected by the assay described in Karl et al. (Karl 1999, Scand J Clin Lab Invest 230:177-181), Yeo et al. (Yeo 2003, Clinica Chimica Acta 338:107-115).
• Variants also include posttranslationally modified peptides such as glycosylated peptides.
• a variant in accordance with the present disclosure is also a peptide or polypeptide which has been modified after collection of the sample, for example by covalent or non-covalent attachment of a label, particularly a radioactive or fluorescent label, to the peptide.
• Determining the amount of a peptide or polypeptide referred to in this specification relates to measuring the amount or concentration, preferably, semi-quantitatively or quantitatively. Measuring can be done directly or indirectly.
• Direct measuring relates to measuring the amount or concentration of the peptide or polypeptide based on a signal which is obtained from the peptide or polypeptide itself and the intensity of which directly correlates with the number of molecules of the peptide present in the sample.
• a signal sometimes referred to herein as intensity signal -may be obtained, e.g., by measuring an intensity value of a specific physical or chemical property of the peptide or polypeptide.
• Indirect measuring includes measuring of a signal obtained from a secondary component (i.e. a component not being the peptide or polypeptide itself) or a biological read out system, e.g., measurable cellular responses, ligands, labels, or enzymatic reaction products.
• determining the amount of a peptide or polypeptide can be achieved by all known means for determining the amount of a peptide in a sample.
• Said means comprise immunoassay and methods which may utilize labeled molecules in various sandwich, competition, or other assay formats.
• Such assays are, preferably, based on detection agents such as antibodies which specifically recognize the peptide or polypeptide to be determined.
• the detection agents shall be either directly or indirectly capable of generating a signal indicating the presence or absence of the peptide or polypeptide.
• the signal strength can, preferably, be correlated directly or indirectly (e.g. reverse-proportional) to the amount of polypeptide present in a sample.
• Further suitable methods comprise measuring a physical or chemical property specific for the peptide or polypeptide such as its precise molecular mass or NMR spectrum.
• Said methods comprise, preferably, biosensors, optical devices coupled to immunoassays, biochips, analytical devices such as mass-spectrometers, NMR— analyzers, or chromatography devices.
• methods include micro-plate ELISA-based methods, fully-automated or robotic immunoassays (available for example on ElecsysTM analyzers), CBA (an enzymatic Cobalt Binding Assay, available for example on Roche-HitachiTM analyzers), and latex agglutination assays (available for example on Roche-HitachiTM analyzers).
• determining the amount of a peptide or polypeptide comprises the steps of (a) contacting a cell capable of eliciting a cellular response the intensity of which is indicative of the amount of the peptide or polypeptide with the said peptide or polypeptide for an adequate period of time, (b) measuring the cellular response.
• the sample or processed sample is, preferably, added to a cell culture and an internal or external cellular response is measured.
• the cellular response may include the measurable expression of a reporter gene or the secretion of a substance, e.g. a peptide, polypeptide, or a small molecule.
• the expression or substance shall generate an intensity signal which correlates to the amount of the peptide or polypeptide.
• determining the amount of a peptide or polypeptide comprises the step of measuring a specific intensity signal obtainable from the peptide or polypeptide in the sample.
• a specific intensity signal may be the signal intensity observed at an m/z variable specific for the peptide or polypeptide observed in mass spectra or a NMR spectrum specific for the peptide or polypeptide.
• Determining the amount of a peptide or polypeptide may, preferably, comprises the steps of (a) contacting the peptide with a specific ligand, (b) (optionally) removing non-bound ligand, (c) measuring the amount of bound ligand.
• said steps of contacting, removing and measuring may be performed by an analyzer unit of the system disclosed herein.
• said steps may be performed by a single analyzer unit of said system or by more than one analyzer unit in operable communication with each other.
• said system disclosed herein may include a first analyzer unit for performing said steps of contacting and removing and a second analyzer unit, operably connected to said first analyzer unit by a transport unit (for example, a robotic arm), which performs said step of measuring.
• binding according to the present disclosure includes both covalent and non-covalent binding.
• a ligand according to the present disclosure can be any compound, e.g., a peptide, polypeptide, nucleic acid, or small molecule, binding to the peptide or polypeptide described herein.
• Preferred ligands include antibodies, nucleic acids, peptides or polypeptides such as receptors or binding partners for the peptide or polypeptide and fragments thereof comprising the binding domains for the peptides, and aptamers, e.g. nucleic acid or peptide aptamers.
• ligands are well-known in the art. For example, identification and production of suitable antibodies or aptamers is also offered by commercial suppliers. The person skilled in the art is familiar with methods to develop derivatives of such ligands with higher affinity or specificity. For example, random mutations can be introduced into the nucleic acids, peptides or polypeptides. These derivatives can then be tested for binding according to screening procedures known in the art, e.g. phage display.
• Antibodies as referred to herein include both polyclonal and monoclonal antibodies, as well as fragments thereof, such as Fv, Fab and F(ab) 2 fragments that are capable of binding antigen or hapten.
• the present disclosure also includes single chain antibodies and humanized hybrid antibodies wherein amino acid sequences of a non-human donor antibody exhibiting a desired antigen-specificity are combined with sequences of a human acceptor antibody.
• the donor sequences will usually include at least the antigen-binding amino acid residues of the donor but may comprise other structurally and/or functionally relevant amino acid residues of the donor antibody as well.
• Such hybrids can be prepared by several methods well known in the art.
• the ligand or agent binds specifically to the peptide or polypeptide. Specific binding according to the present disclosure means that the ligand or agent should not bind substantially to (“cross-react” with) another peptide, polypeptide or substance present in the sample to be analyzed.
• the specifically bound peptide or polypeptide should be bound with at least 3 times higher, more preferably at least 10 times higher and even more preferably at least 50 times higher affinity than any other relevant peptide or polypeptide.
• Non-specific binding may be tolerable, if it can still be distinguished and measured unequivocally, e.g. according to its size on a Western Blot, or by its relatively higher abundance in the sample.
• Binding of the ligand can be measured by any method known in the art. Preferably, said method is semi-quantitative or quantitative. Further suitable techniques for the determination of a polypeptide or peptide are described in the following.
• binding of a ligand may be measured directly, e.g. by NMR or surface plasmon resonance. Measurement of the binding of a ligand, according to preferred embodiments, is performed by an analyzer unit of a system disclosed herein. Thereafter, an amount of the measured binding may be calculated by a computing device of a system disclosed herein. Second, if the ligand also serves as a substrate of an enzymatic activity of the peptide or polypeptide of interest, an enzymatic reaction product may be measured (e.g. the amount of a protease can be measured by measuring the amount of cleaved substrate, e.g. on a Western Blot).
• the ligand may exhibit enzymatic properties itself and the “ligand/peptide or polypeptide” complex or the ligand which was bound by the peptide or polypeptide, respectively, may be contacted with a suitable substrate allowing detection by the generation of an intensity signal.
• a suitable substrate allowing detection by the generation of an intensity signal.
• the amount of substrate is saturating.
• the substrate may also be labeled with a detectable label prior to the reaction.
• the sample is contacted with the substrate for an adequate period of time.
• An adequate period of time refers to the time necessary for an detectable, preferably measurable, amount of product to be produced. Instead of measuring the amount of product, the time necessary for appearance of a given (e.g. detectable) amount of product can be measured.
• the ligand may be coupled covalently or non-covalently to a label allowing detection and measurement of the ligand.
• Labeling may be done by direct or indirect methods. Direct labeling involves coupling of the label directly (covalently or non-covalently) to the ligand. Indirect labeling involves binding (covalently or non-covalently) of a secondary ligand to the first ligand. The secondary ligand should specifically bind to the first ligand. Said secondary ligand may be coupled with a suitable label and/or be the target (receptor) of tertiary ligand binding to the secondary ligand. The use of secondary, tertiary or even higher order ligands is often used to increase the signal.
• Suitable secondary and higher order ligands may include antibodies, secondary antibodies, and the well-known streptavidin-biotin system (Vector Laboratories, Inc.).
• the ligand or substrate may also be “tagged” with one or more tags as known in the art. Such tags may then be targets for higher order ligands.
• Suitable tags include biotin, digoxygenin, His-Tag, Glutathion-S-Transferase, FLAG, GFP, myc-tag, influenza A virus haemagglutinin (HA), maltose binding protein, and the like.
• the tag is preferably at the N-terminus and/or C-terminus.
• Suitable labels are any labels detectable by an appropriate detection method.
• Typical labels include gold particles, latex beads, acridan ester, luminol, ruthenium, enzymatically active labels, radioactive labels, magnetic labels (“e.g. magnetic beads”, including paramagnetic and superparamagnetic labels), and fluorescent labels.
• Enzymatically active labels include e.g. horseradish peroxidase, alkaline phosphatase, beta-Galactosidase, Luciferase, and derivatives thereof.
• Suitable substrates for detection include di-amino-benzidine (DAB), 3,3′-5,5′-tetramethylbenzidine, NBT-BCIP (4-nitro blue tetrazolium chloride and 5-bromo-4-chloro-3-indolyl-phosphate, available as ready-made stock solution from Roche Diagnostics), CDP-StarTM (Amersham Biosciences), ECFTM (Amersham Biosciences).
• a suitable enzyme-substrate combination may result in a colored reaction product, fluorescence or chemoluminescence, which can be measured according to methods known in the art (e.g. using a light-sensitive film or a suitable camera system). As for measuring the enyzmatic reaction, the criteria given above apply analogously.
• Typical fluorescent labels include fluorescent proteins (such as GFP and its derivatives), Cy3, Cy5, Texas Red, Fluorescein, and the Alexa dyes (e.g. Alexa 568). Further fluorescent labels are available e.g. from Molecular Probes (Oregon). Also the use of quantum dots as fluorescent labels is contemplated.
• Typical radioactive labels include 35S, 125I, 32P, 33P and the like. A radioactive label can be detected by any method known and appropriate, e.g. a light-sensitive film or a phosphor imager.
• Suitable measurement methods also include precipitation (particularly immunoprecipitation), electrochemiluminescence (electro-generated chemiluminescence), RIA (radioimmunoassay), ELISA (enzyme-linked immunosorbent assay), sandwich enzyme immune tests, electrochemiluminescence sandwich immunoassays (ECLIA), dissociation-enhanced lanthanide fluoro immuno assay (DELFIA), scintillation proximity assay (SPA), turbidimetry, nephelometry, latex-enhanced turbidimetry or nephelometry, or solid phase immune tests.
• precipitation particularly immunoprecipitation
• electrochemiluminescence electrochemiluminescence (electro-generated chemiluminescence)
• RIA radioimmunoassay
• ELISA enzyme-linked immunosorbent assay
• sandwich enzyme immune tests sandwich enzyme immune tests
• electrochemiluminescence sandwich immunoassays ELIA
• the amount of a peptide or polypeptide may be, also preferably, determined as follows: (a) contacting a solid support comprising a ligand for the peptide or polypeptide as specified above with a sample comprising the peptide or polypeptide and (b) measuring the amount peptide or polypeptide which is bound to the support.
• the ligand preferably chosen from the group consisting of nucleic acids, peptides, polypeptides, antibodies and aptamers, is preferably present on a solid support in immobilized form.
• Materials for manufacturing solid supports include, inter alia, commercially available column materials, polystyrene beads, latex beads, magnetic beads, colloid metal particles, glass and/or silicon chips and surfaces, nitrocellulose strips, membranes, sheets, duracytes, wells and walls of reaction trays, plastic tubes etc.
• the ligand or agent may be bound to many different carriers. Examples of well-known carriers include glass, polystyrene, polyvinyl chloride, polypropylene, polyethylene, polycarbonate, dextran, nylon, amyloses, natural and modified celluloses, polyacrylamides, agaroses, and magnetite.
• the nature of the carrier can be either soluble or insoluble for the purposes of the disclosure.
• Suitable methods for fixing/immobilizing said ligand are well known and include, but are not limited to ionic, hydrophobic, covalent interactions and the like. It is also contemplated to use “suspension arrays” as arrays according to the present disclosure (Nolan 2002, Trends Biotechnol. 20(1):9-12).
• the carrier e.g. a microbead or microsphere
• the array consists of different microbeads or microspheres, possibly labeled, carrying different ligands.
• Methods of producing such arrays for example based on solid-phase chemistry and photo-labile protective groups, are generally known (U.S. Pat. No. 5,744,305).
• amount encompasses the absolute amount of a polypeptide or peptide, the relative amount or concentration of the said polypeptide or peptide as well as any value or parameter which correlates thereto or can be derived therefrom.
• values or parameters comprise intensity signal values from all specific physical or chemical properties obtained from the said peptides by direct measurements, e.g., intensity values in mass spectra or NMR spectra.
• values or parameters which are obtained by indirect measurements specified elsewhere in this description e.g., response amounts determined from biological read out systems in response to the peptides or intensity signals obtained from specifically bound ligands.
• the determination of an “amount” is performed by the disclosed system, whereby a computing device determines the “amount” based on contacting and measuring steps performed by one or more analyzer units of said system.
• comparing encompasses comparing the amount of the peptide or polypeptide comprised by the sample to be analyzed with an amount of a suitable reference source specified elsewhere in this description. It is to be understood that comparing as used herein refers to a comparison of corresponding parameters or values, e.g., an absolute amount is compared to an absolute reference amount while a concentration is compared to a reference concentration or an intensity signal obtained from a test sample is compared to the same type of intensity signal of a reference sample.
• the comparison referred to in step (b) of the method of the present disclosure may be carried out manually or computer assisted.
• the comparison referred to in step (b) of the method of the present disclosure may be carried out by a computing device (e.g., of a system disclosed herein).
• the value of the amount and the reference can be, e.g., compared to each other and the said comparison can be automatically carried out by a computer program executing an algorithm for the comparison.
• the computer program carrying out the said evaluation will provide the desired assessment in a suitable output format.
• the value of the determined amount may be compared to values corresponding to suitable references which are stored in a database by a computer program.
• the computer program may further evaluate the result of the comparison, i.e. automatically provide the desired assessment in a suitable output format.
• the value of the determined amount may be compared to values corresponding to suitable references which are stored in a database by a computer program.
• the computer program may further evaluate the result of the comparison, i.e. automatically provides the desired assessment in a suitable output format.
• the said result may, preferably, serve as an aid in differentiating between cardioembolic and non-cardioembolic ischemic stroke.
• a result of a comparison may be given as raw data (absolute or relative amounts), and in some cases as an indicator in the form of a word, phrase, symbol, or numerical value which may be indicative of a particular diagnosis.
• reference amount refers to an amount which allows for allocation of a subject into either the group of subjects suffering from cardioembolic ischemic stroke or into a group of subject suffering from non-cardioembolic ischemic stroke.
• a reference amount can be a threshold amount which separates these groups from each other.
• the reference amount for a the biomarker Troponin shall be an amount which allows for allocation of a subject into a group of subjects suffering from cardioembolic ischemic stroke or into a group of subjects suffering from non-cardioembolic ischemic stroke.
• a suitable threshold amount separating the two groups can be calculated without further ado by the statistical tests referred to herein elsewhere based on amounts of a cardiac Troponin from either a subject or group of subjects suffering from cardioembolic ischemic stroke or a subject or group of subjects suffering from non-cardioembolic ischemic stroke. Preferred referenced amounts which can be derived from the aforementioned subjects or group of subjects are indicated elsewhere herein.
• Reference amounts can, in principle, be calculated for a cohort of subjects as specified above based on the average or mean values for a given biomarker by applying standard statistically methods.
• accuracy of a test such as a method aiming to diagnose an event, or not, is best described by its receiver-operating characteristics (ROC) (see especially Zweig 1993, Clin. Chem. 39:561-577).
• ROC receiver-operating characteristics
• the ROC graph is a plot of all of the sensitivity/specificity pairs resulting from continuously varying the decision threshold over the entire range of data observed.
• the clinical performance of a diagnostic method depends on its accuracy, i.e. its ability to correctly allocate subjects to a certain prognosis or diagnosis.
• the ROC plot indicates the overlap between the two distributions by plotting the sensitivity versus 1-specificity for the complete range of thresholds suitable for making a distinction.
• sensitivity or the true-positive fraction, which is defined as the ratio of number of true-positive test results to the product of number of true-positive and number of false-negative test results. This has also been referred to as positivity in the presence of a disease or condition. It is calculated solely from the affected subgroup.
• the false-positive fraction, or 1-specificity which is defined as the ratio of number of false-positive results to the product of number of true-negative and number of false-positive results. It is an index of specificity and is calculated entirely from the unaffected subgroup.
• the ROC plot is independent of the prevalence of the event in the cohort.
• Each point on the ROC plot represents a sensitivity/-specificity pair corresponding to a particular decision threshold.
• a test with perfect discrimination has an ROC plot that passes through the upper left corner, where the true-positive fraction is 1.0, or 100% (perfect sensitivity), and the false-positive fraction is 0 (perfect specificity).
• the theoretical plot for a test with no discrimination is a 45° diagonal line from the lower left corner to the upper right corner. Most plots fall in between these two extremes.
• a threshold can be derived from the ROC curve allowing for the diagnosis or prediction for a given event with a proper balance of sensitivity and specificity, respectively.
• the reference to be used for the aforementioned method of the present disclosure can be, preferably, a threshold or cut off amount and can be generated, preferably, by establishing a ROC for said cohort as described above and deriving a threshold amount therefrom.
• the ROC plot allows deriving suitable thresholds.
• the diagnosis/differentiation referred to herein may be provided by the computing device of a system disclosed herein based on said comparison of the calculated “amount” to a reference or a threshold.
• a computing device of a system may provide an indicator, in the form of a word, symbol, or numerical value which is indicative of one cardioembolic stroke or non-cardioembolic stroke.
• the reference amount(s) is (are) derived from a subject or a group of subjects known to suffer from cardioembolic ischemic stroke.
• an essentially identical amount or an increased amount of a cardiac Troponin in the test sample as compared to reference amount is, preferably, indicative for cardioembolic ischemic stroke.
• a natriuretic peptide is determined, an essentially identical amount or an increased amount of a cardiac Troponin and of the natriuretic peptide in the test sample as compared to reference amount for the cardiac Troponin and the reference amount for the natriuretic peptide is, preferably, indicative for cardioembolic ischemic stroke.
• the reference amount for a cardiac Troponin may be derived from a subject or a group of subjects known to suffer from non-cardioembolic ischemic stroke.
• an essentially identical amount or a decreased amount of the cardiac Troponin (and, optionally, of the natriuretic peptide) in the test sample as compared to reference amount is indicative for non-cardioembolic ischemic stroke.
• an essentially identical amount or a decreased amount of the cardiac Troponin of the natriuretic peptide in the test sample as compared to the reference amount for the cardiac Troponin and the reference amount for the natriuretic peptide is indicative for non-cardioembolic ischemic stroke.
• the reference amount applicable for an individual subject may vary depending on various physiological parameters such as age, gender, or subpopulation, as well as on the means used for the determination of the polypeptide or peptide referred to herein.
• a suitable reference amount may be determined from a reference sample to be analyzed together, i.e. simultaneously or subsequently, with the test sample.
• the reference amount may define a threshold amount, in particular a calculated reference amount, for the cardiac Troponin (and, optionally for the natriuretic peptide), whereby an amount of Troponin (and, optionally of the natriuretic peptide) in the sample of the test subject larger than the respective threshold shall be indicative for cardioembolic ischemic stroke, while an amount of Troponin (and, optionally, of the natriuretic peptide) in the sample of the test subject lower than the respective threshold shall be indicative for non-cardioembolic stroke.
• a threshold amount in particular a calculated reference amount, for the cardiac Troponin (and, optionally for the natriuretic peptide)
• a preferred reference amount indicating cardioembolic ischemic stroke is an amount of a cardiac troponin, in particular of Troponin T of about 8 pg/ml to about 40 pg/ml and, more preferably, 10 to 30 pg/ml, about 11.6 to about 20 pg/ml, even more preferably of about 15 to 20 pg/ml. Even more preferably, the reference is an amount of about 8, 10, or 11.6 pg/ml.
• a test amount being essentially identical or increased shall be indicative for cardioembolic ischemic stroke while a decreased amount in the test sample as compared to the reference amount shall be indicative for non-cardioembolic ischemic stroke.
• the aforementioned reference amounts are derived from a subject or a group of subjects known to suffer from cardioembolic ischemic stroke.
• a test amount of a cardiac Troponin, preferably, of Troponin T, being lower than 5 pg/ml, in particular lower than 3 or lower than 2 pg/mg indicates that the subject does not suffer from cardioembolic stroke (and, thus, preferably, suffers from non-cardioembolic stroke).
• a preferred reference amount indicating cardioembolic ischemic stroke is an amount of a natriuretic peptide, in particular, of NT-proBNP of about 500 pg/ml to about 1500 pg/ml and, more preferably, 700 to 1300 pg/ml, even more preferably of about 800 to 1000 pg/ml. Even more preferably, the reference is an amount of about 700, 800, or most preferably 900 pg/ml.
• a test amount being essentially identical or increased shall be indicative for cardioembolic ischemic stroke while a decreased amount in the test sample as compared to the reference amount shall be indicative for non-cardioembolic ischemic stroke.
• the aforementioned reference amounts are derived from a subject or a group of subjects known to suffer from cardioembolic ischemic stroke (in addition to the amount of the cardiac Troponin).
• a test amount of a natriuretic peptide, in particular of NT-proBNP being lower than 250 pg/ml, in particular lower than 200 or lower than 150 pg/mg indicates that the subject does not suffer from cardioembolic stroke (and, thus, preferably, suffers from non-cardioembolic stroke).
• said method further comprises recommending a therapy for said subject, in particular, if the subject has been diagnosed to suffer from cardioembolic stroke.
• a therapy that can be recommended in a subject who suffers from cardioembolic stroke is lytic therapy and/or anticoagulation therapy (see e.g. Cairns J. A. et al Canadian J of Cardiology 2011: 27: 74-90 or Camm A. J. et al Eur Heart Journal 2010:31:2369-429 which are both incorporated herein by reference).
• a method for differentiating whether a subject suffers from cardioembolic ischemic stroke or from non-cardioembolic ischemic stroke comprising:
• the amount of a natriuretic peptide is determined.
• a system for differentiating whether a subject suffers from cardioembolic ischemic stroke or from non-cardioembolic ischemic stroke comprising:
• the system also comprises a detection agent that specifically binds to natriuretic peptide.
• a suitable detection agent may be, in an aspect, an antibody which is specifically binds to the cardiac troponin, in a sample of a subject to be investigated by the method of the disclosure.
• Another detection agent that can be applied in an aspect, may be an aptamere which specifically binds to the marker in the sample.
• sample is removed from the complex formed between the detection agent and the marker prior to the measurement of the amount of formed complex.
• the detection agent may be immobilized on a solid support.
• the sample can be removed from the formed complex on the solid support by applying a washing solution. The formed complex shall be proportional to the amount of the marker present in the sample.
• the specificity and/or sensitivity of the detection agent to be applied defines the degree of proportion of at least one marker comprised in the sample which is capable of being specifically bound. Further details on how the determination can be carried out are also found elsewhere herein.
• the amount of formed complex shall be transformed into an amount of the marker reflecting the amount indeed present in the sample. Such an amount, in an aspect, may be essentially the amount present in the sample or may be, in another aspect, an amount which is a certain proportion thereof due to the relationship between the formed complex and the amount present in the original sample.
• step a) may be carried out by an analyzer unit, in an aspect, an analyzer unit as defined elsewhere herein.
• the amount determined in step a) is compared to a reference.
• the reference is a reference as defined elsewhere herein.
• the reference takes into account the proportional relationship between the measured amount of complex and the amount present in the original sample.
• the references applied in an aspect of the method of the disclosure are artificial references which are adopted to reflect the limitations of the detection agent that has been used.
• said relationship can be also taken into account when carrying out the comparison, e.g., by including a normalization and/or correction calculation step for the determined amount prior to actually comparing the value of the determined amount and the reference.
• the normalization and/or correction calculation step for the determined amount adopts the comparison step such that the limitations of the detection agent that has been used are reflected properly.
• the comparison is carried out automatically, e.g., assisted by a computer system or the like.
• the aid for differentiating whether a subject suffers from cardioembolic ischemic stroke or from non-cardioembolic ischemic stroke is established based on the comparison carried out in step b) by allocating the subject either (i) the group of subjects who suffer from cardioembolic stroke or (ii) the group of who suffer from non-cardioembolic stroke as set forth herein elsewhere.
• the allocation of the investigated subject must not be correct in 100% of the investigated cases.
• the groups of subjects into which the investigated subject is allocated are artificial groups in that they are established based on statistical considerations, i.e. a certain preselected degree of likelihood based on which the method of the disclosure shall operate.
• the aid for the differentiation is established automatically, e.g., assisted by a computing device or the like, as described and disclosed herein.
• said method further comprises a step of recommending and/or managing the subject according to the result established in step c) as set forth elsewhere herein in detail.
• steps b) and/or c) are carried out by one or more analyzer units as set forth elsewhere herein.
• Atrial fibrillation is frequently no recognised by the patient. This is the case in approximately 40% of patients indicating that history taking in insensitive for the diagnosis of atrial fibrillation (Kamel H. et al, Curr Atheroscler Rep 2011:13:338-343). While these numbers relate to persistent atrial fibrillation, paroxysmal atrial fibrillation is even more difficult to diagnose and can only be captured by inpatient cardiac telemetry or even Jolter Monitoring. The latter having the advantage, that the ECG is recorded and can later on be reviewed by an experienced physician. Using Holter ECG paroxysmal—previously unrecognised atrial fibrillation was more frequent than persistent atrial fribillation (Rizos T. et all. Cerebrovasc.
• the inventors have found that the determination of a cardiac Troponin allows for diagnosing atrial fibrillation. Interestingly, patients with intermittent AF had also increased cardiac Troponin levels. Therefore, also patients exhibiting intermittent AF can be identified by determining the amount of cardiac Troponin.
• the present disclosure relates to a method for diagnosing atrial fibrillation in a subject suspected to suffer from atrial fibrillation, comprising a) determining the amount of a cardiac Troponin in a sample from said subject.
• the present disclosure relates to a method for diagnosing atrial fibrillation in a subject suspected to suffer from atrial fibrillation, comprising
• the diagnosis whether a subject suffers from atrial fibrillation, or not by carrying out the further step c) of diagnosing whether the subject suffers from atrial fibrillation, or not.
• intermittent atrial fibrillation is diagnosed.
• the present disclosure in particular relates to a method for diagnosing intermittent atrial fibrillation in a subject suspected to suffer from atrial fibrillation, comprising
• step a) further comprises the determination of the amount of a natriuretic peptide in the sample from the subject.
• the, thus, determined amount of the natriuretic peptide is compared in step b) to a reference amount for a natriuretic peptide.
• the present disclosure also relates to a method for diagnosing atrial fibrillation in a subject suspected to suffer from atrial fibrillation, comprising
• Atrial fibrillation is well known in the art. Atrial fibrillation is e.g. reviewed by Fuster et al. which herewith is incorporated by reference in its entire disclosure content (Fuster V, Rydén LE, Asinger R W, et al. ACC/AHA/ESC Guidelines for the Management of Patients With Atrial Fibrillation: Executive Summary A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to Develop Guidelines for the Management of Patients With Atrial Fibrillation) Developed in Collaboration With the North American Society of Pacing and Electrophysiology. Circulation. Oct. 23 2001; 104(17):2118-50).
• Atrial fibrillation is an abnormal heart rhythm which involves the two upper chambers of the heart.
• the impulse generated by the sino-atrial node spreads through the heart and causes contraction of the heart muscle and pumping of blood.
• the regular electrical impulses of the sino-atrial node are replaced by disorganized, rapid electrical impulses which result in irregular heart beats.
• Atrial fibrillation can be permanent, persistent or intermittent (for an explanation of these terms, see also Fuster et al. (loc. cit.).
• a subject preferably, suffers from permanent AF, if the AF has persisted for more than one year. In particular, conversion back to sinus rhythm does not occur (or only if treated).
• a subject preferably, suffers from persistent AF, if the AF lasts more than 7 days and may require either pharmacologic or electrical intervention to terminate atrial fibrillation. Thus persistent AF occurs in episodes, but the arrhythmia does not convert back to sinus rhythm spontaneously.
• a subject preferably, suffers from intermittent AF (frequently also referred to as paroxymal AF), if there are episodes of atrial fibrillation that terminate spontaneously.
• the episodes of atrial fibrillation may last from seconds to days. Preferably, the episodes last less than one hour.
• intermittent atrial fibrillation is diagnosed.
• Permanent and persistent atrial fibrillation can be easily diagnosed, e.g., on an electrocardiogram. Characteristic findings are, preferably, the absence of P waves, unorganized electrical activity in their place, and irregularity of R—R interval due to irregular conduction of impulses to the ventricles. Intermittent atrial fibrillation is more difficult to diagnose, since a diagnosis is only possible during the episode of atrial fibrillation.
• the inventors have surprisingly found that the determination of a cardiac Troponin (and, optionally of natriuretic peptide) in a sample of a subject suspected to suffer from atrial fibrillation allows for the diagnosis of atrial fibrillation.
• increased levels of a cardiac Troponin are indicative for a subject suffering AF
• decreased levels of a cardiac Troponin are indicative for a subject not suffering from AF.
• the determination of a cardiac Troponin also allows for the diagnosis of intermittent AF, even in the absence of an episode of AF (at the time point at which the sample is obtained).
• intermittent atrial fibrillation is, preferably, diagnosed in the absence of an episode of atrial fibrillation, in particular at the time point at which the sample is obtained.
• the subject preferably, does not suffer from an episode of AF when the sample is obtained.
• the subject in accordance with the aforementioned method of the present disclosure shall be suspected to suffer from atrial fibrillation.
• a subject suspected to suffer from atrial fibrillation e.g. from intermittent atrial fibrillation
• risk factors are well known in the art and include heart disease, including valve problems and a history of heart attack and heart surgery, systemic hypertension, especially if it's not well controlled with lifestyle changes or medications, and alcohol consumption.
• the subject being suspected to belongs to a risk group.
• the subject is a subject with proven or suspected cardiac disorders including subjects having risk factors predisposing to cardiac disorders such as arterial or systemic hypertension, diabetes mellitus, smokers, individuals with hyperlipemia or signs of the metabolic syndrome, in particular if the subject is at advanced age (more than 60, 65, 70 and preferably 75 years of age).
• the subject may, preferably, suffer from valvular disorders, preferably from mitral valve disorders.
• the subject suspected to suffer from AF suffers from hyperthyroidism.
• the subject who is suspected to suffer from atrial fibrillation preferably, suffers from ischemic stroke, in particular from cardioembolic ischemic stroke (for an explanation of the these terms, see elsewhere herein).
• the sample is, preferably, obtained immediately after the onset of stroke symptoms as described in the context of the method for early differentiating whether a subject suffers from cardioembolic stroke or from non-cardioembolic ischemic stroke.
• the subject to be tested does not suffer from ischemic stroke.
• the reference amount in connection with the aforementioned method is derived from a subject known to suffer from atrial fibrillation (or from a group of subjects), and wherein an identical amount of the cardiac Troponin (and, optionally, of the natriuretic peptide), or an amount of the cardiac Troponin (and, optionally, of the natriuretic peptide) which is increased as compared to the reference amount, indicates that the subject suffers from atrial fibrillation.
• the reference amount is derived from a subject known not to suffer from atrial fibrillation or from a group of such subjects, wherein an identical amount of the cardiac Troponin (and, optionally, of the natriuretic peptide), or an amount of the cardiac troponin Troponin (and, optionally, of the natriuretic peptide) which is decreased as compared to the reference amount, indicates that the subject does not suffer from atrial fibrillation.
• the reference amount may define a threshold amount for the cardiac Troponin (and, optionally for the natriuretic peptide), whereby an amount of Troponin (and, optionally of the natriuretic peptide) in the sample of the test subject larger than the respective threshold shall be indicative for atrial fibrillation, while an amount of Troponin (and, optionally, of the natriuretic peptide) in the sample of the test subject lower than the respective threshold shall indicate that the subject does not suffer from atrial fibrillation.
• a preferred reference amount indicating atrial fibrillation is an amount of a cardiac troponin, in particular of Troponin T of about 6 pg/ml to about 40 pg/ml and, more preferably, 8 to 30 pg/ml, or about 10 to about 20 pg/ml, even more preferably of about 15 to 20 pg/ml. Even more preferably, the reference is an amount of about 10 pg/ml, or most preferably, about 7 pg/ml.
• a test amount being essentially identical or increased shall be indicative for atrial fibrillation while a decreased amount in the test sample as compared to the reference amount shall indicate that the subject does not suffer from atrial fibrillation.
• the aforementioned reference amounts are derived from a subject or a group of subjects known to suffer from atrial fibrillation.
• An exemplary reference amount indicating atrial fibrillation is an amount of a natriuretic peptide, in particular, of NT-proBNP of about 300 pg/ml to about 1500 pg/ml and, more preferably, 400 to 1300 pg/ml, even more preferably of about 500 to 1000 pg/ml. Even more preferably, the reference is an amount of about 500, 400, or most preferably, of about 300 pg/ml.
• a test amount being essentially identical or increased shall be indicative for atrial fibrillation while a decreased amount in the test sample as compared to the reference amount shall indicate that the subject does not suffer from atrial fibrillation.
• the aforementioned reference amounts are derived from a subject or a group of subjects known to suffer from atrial fibrillation.
• intermittent atrial fibrillation shall be diagnosed, in particular in subject suspected to suffer from intermittent atrial fibrillation.
• the amount of the cardiac Troponin, and, optionally, the amount of the natriuretic peptide, as determined in step a) shall be compared in step b) to two reference amounts. It is envisaged that a first reference amount is derived from a subject known to suffer from intermittent AF (or from a group of such subjects), and that a second reference amount is derived from a subject known to suffer from permanent or, in particular, from persistent AF (or from a group of such subjects). Of course, the reference amounts shall be derived from samples of the aforementioned subjects.
• an amount of the cardiac Troponin and, optionally, of the natriuretic peptide in the sample of the test subject which is essentially identical or larger than the than the reference amount (for the cardiac Troponin and, optionally, for the natriuretic peptide) derived from a subject known to suffer from intermittent AF (or from a group of such subjects), but which is lower than the reference amount derived from a subject known to suffer from permanent or from persistent AF (or from a group of such subjects) is indicative for the diagnosis of intermittent AF.
• a preferred reference amount for a cardiac Troponin, in particular for Troponin T, derived from a subject known to suffer from intermittent AF (or from a group of such subjects) is within a range of about 5 to 10 pg/ml. Preferably, the reference amount is about 9 pg/ml.
• a preferred reference amount for a cardiac Troponin, in particular for Troponin T, derived from a subject known to suffer from permanent or from persistent AF (or from a group of such subjects) is within a range of about 12 to 25 pg/ml. Preferably, the reference amount is about 18 pg/ml.
• a preferred reference amount for a natriuretic peptide, in particular for NT-proBNP, derived from a subject known to suffer from intermittent AF (or from a group of such subjects) is within a range of about 300 to 500 pg/ml. Preferably, the reference amount is about 350 pg/ml.
• a preferred reference amount for a natriuretic peptide, in particular for NT-proBNP, derived from a subject known to suffer from permanent or from persistent AF (or from a group of such subjects) is within a range of about 900 to 1500 pg/ml. Preferably, the reference amount is about 900 pg/ml.
• intermittent AF is diagnosed.
• the subject according to this preferred embodiment shall be known not to suffer from permanent and/or persistent atrial fibrillation (which can be determined without further ado, see above).
• the subject suspected to suffer from intermittent AF preferably, has the same risk factors as the subject suspected to suffer from AF (see elsewhere herein).
• the subject suffers from ischemic stroke, in particular from cardioembolic ischemic stroke.
• the reference amount to be applied in the context of the present disclosure shall be derived from a subject known to suffer from intermittent AF, or from a subject known not to suffer from AF.
• the reference amount in connection with the aforementioned embodiment is derived from a subject known to suffer from intermittent atrial fibrillation (or from a group of subjects), and wherein an identical amount of the cardiac Troponin (and, optionally, of the natriuretic peptide), or an amount of the cardiac Troponin (and, optionally, of the natriuretic peptide) which is increased as compared to the reference amount, indicates that the subject suffers intermittent atrial fibrillation.
• the reference amount is derived from a subject known not to suffer from atrial fibrillation, wherein an identical amount of the cardiac Troponin (and, optionally, of the natriuretic peptide), or an amount of the cardiac troponin Troponin (and, optionally, of the natriuretic peptide) which is decreased as compared to the reference amount, indicates that subject does not suffer from intermittent atrial fibrillation.
• a preferred reference amount indicating intermittent atrial fibrillation is an amount of a cardiac troponin, in particular of Troponin T of about 5 pg/ml to about 30 pg/ml and, more preferably, 5 to 25 pg/ml, or about 6 to about 10 pg/ml, even more preferably of about 6 to 8 pg/ml. Even more preferably, the reference is an amount of about 8 pg/ml, or most preferably, about 7 pg/ml.
• a test amount being essentially identical or increased shall be indicative for intermittent atrial fibrillation while a decreased amount in the test sample as compared to the reference amount shall indicate that the subject does not suffer from intermittent atrial fibrillation.
• the aforementioned reference amounts are derived from a subject or a group of subjects known to suffer from intermittent atrial fibrillation.
• a preferred reference amount indicating intermittent atrial fibrillation is an amount of a natriuretic peptide, in particular, of NT-proBNP of about 300 pg/ml to about 800 pg/ml and, more preferably, 300 to 700 pg/ml, even more preferably of about 350 to 500 pg/ml. Even more preferably, the reference is an amount of about 500, 400, or most preferably, of about 300 pg/ml.
• a test amount being essentially identical or increased shall be indicative for intermittent atrial fibrillation while a decreased amount in the test sample as compared to the reference amount shall indicate that the subject does not suffer from intermittent atrial fibrillation.
• the aforementioned reference amounts are derived from a subject or a group of subjects known to suffer from intermittent atrial fibrillation.
• said method further comprises recommending a therapy for said subject, if the subject has been diagnosed to suffer atrial fibrillation, in particular from intermittent atrial fibrillation.
• Preferred therapies that can be recommended in a subject who suffers from atrial fibrillation are, e.g., described by Fuster et al. (Fuster et al. J Am Coll Cardiol 2001:38:1231, and Fuster V. et al. Circulation 2006: 114 to 257).
• Preferred therapies included, administration of beta blockers, non-dihydropyridine calcium channel blockers, digoxin, vitamin K antatgonists, aspirin, acetylsalicylic acid.
• Pharmacologic intervention can be recommended to terminate atrial fibrillation.
• Pharmacologic intervention preferably, include administration of flecamide, dofetilide, propafenone and/or ibutilide.
• factor Xa inhibitors such as rivaroxoban and/or dabigatran (see Patel M. R. et al, NEJM 2011: 365: 883-91; Connolly S. J. et al NEJM 2010:261:1139-51).
• intermittent atrial fibrillation is diagnosed.
• the subject does not suffer from ischemic stroke.
• the subject suspected to suffer from atrial fibrillation suffers from ischemic stroke, in particular from cardioembolic stroke, and wherein the sample has been obtained immediately after the onset of symptoms of ischemic stroke.
• the sample from said subject has been obtained from said subject not more than 12 hours after the onset of symptoms of ischemic stroke, in particular not more than 6 hours or not more than 3 hours after the onset of symptoms of ischemic stroke.
• the reference amount is derived from a subject known to suffer from intermittent atrial fibrillation or from a group of such subjects, and wherein an identical amount of the cardiac Troponin, or an amount of the cardiac Troponin which is increased as compared to the reference amount, indicates that the subject suffers intermittent atrial fibrillation, and/or wherein the reference amount is derived from a subject known not to suffer from atrial fibrillation or from a group of such subjects, wherein an identical amount of the cardiac Troponin, or an amount of the cardiac troponin Troponin which is decreased as compared to the reference amount, indicates that subject does not suffer from intermittent atrial fibrillation.
• the amount of the cardiac Troponin in the sample from the subject is compared to two reference amounts, wherein the first reference amount is derived from a subject known to suffer from intermittent AF or from a group of such subjects, and wherein the second reference amount is derived from a subject known to suffer from permanent or from persistent AF or from a group of such subjects.
• an amount of the cardiac Troponin in the sample of the subject which is essentially identical or larger than the than the first reference amount, but which is lower than the second reference amount derived from a subject known to suffer from permanent or from persistent AF is indicative for the diagnosis of intermittent AF.
• the method further comprises the determination of the amount of a natriuretic peptide, in particular of a brain natriuretic peptide, in particular of BNP and NT-proBNP.
• intermittent atrial fibrillation is diagnosed in the absence of an episode of atrial fibrillation, in particular at the time point at which the sample is obtained.
• a system for diagnosing AF, in particular, intermittent AF comprising:
• the system also comprises a detection agent that specifically binds to natriuretic peptide.
• step a) may be carried out by an analyzer unit, in an aspect, an analyzer unit as defined elsewhere herein.
• the amount determined in step a) is compared to a reference.
• the reference is a reference as defined elsewhere herein.
• the reference takes into account the proportional relationship between the measured amount of complex and the amount present in the original sample.
• the references applied in an aspect of the method of the disclosure are artificial references which are adopted to reflect the limitations of the detection agent that has been used.
• said relationship can be also taken into account when carrying out the comparison, e.g., by including a normalization and/or correction calculation step for the determined amount prior to actually comparing the value of the determined amount and the reference.
• the normalization and/or correction calculation step for the determined amount adopts the comparison step such that the limitations of the detection agent that has been used are reflected properly.
• the comparison is carried out automatically, e.g., assisted by a computer system or the like.
• the aid for diagnosing AF, in particular, intermittent AF is established based on the comparison carried out in step b) by allocating the subject either (i) the group of subjects who suffer from AF or (ii) the group of who do not suffer from AF as set forth herein elsewhere.
• the allocation of the investigated subject must not be correct in 100% of the investigated cases.
• the groups of subjects into which the investigated subject is allocated are artificial groups in that they are established based on statistical considerations, i.e. a certain preselected degree of likelihood based on which the method of the disclosure shall operate.
• the aid for optimizing a risk assessment is established automatically, e.g., assisted by a computing device or the like, as described and disclosed herein.
• said method further comprises a step of recommending and/or managing the subject according to the result established in step c) as set forth elsewhere herein in detail.
• steps b) and/or c) are carried out by one or more analyzer units as set forth elsewhere herein.
• the present disclosure relates to the use of a cardiac Troponin and/or of a detection agent, which specifically binds thereto (and optionally of a natriuretic peptide and/or of detection agent, which specifically binds thereto) in a sample of a subject suffering from ischemic stroke for early differentiating whether the subject suffers from cardioembolic ischemic stroke or from non-cardioembolic ischemic stroke, wherein the sample has been obtained immediately after the onset of symptoms of ischemic stroke.
• said sample has been obtained not more than 6 hours after the onset of symptoms of stroke.
• a cardiac Troponin and/or of a detection agent which specifically binds thereto (and optionally of a natriuretic peptide and/or of detection agent, which specifically binds thereto) in a sample of a subject suspected to suffer from atrial fibrillation for diagnosing atrial fibrillation in a said subject.
• atrial fibrillation Preferably, intermittent atrial fibrillation is diagnosed.
• detection agent refers to an agent which is capable of specifically recognizing and binding the biomarker referred to herein (a cardiac Troponin, or a natriuretic peptide) when present in a sample.
• said agent shall allow for direct or indirect detection of the complex formed by the said agent and the biomarker. Direct detection can be achieved by including into the agent a detectable label. Indirect labelling may be achieved by a further agent which specifically binds to the complex comprising the biomarker and the detection agent wherein the said further agent is than capable of generating a detectable signal. Suitable compounds which can be used as detection agents are well known in the art.
• the detection agent is an antibody or aptamere which specifically binds to the biomarker.
• Antibodies as referred to herein include both polyclonal and monoclonal antibodies, as well as fragments thereof, such as Fv, Fab and F(ab) 2 fragments that are capable of binding antigen or hapten. Also envisaged are single chain antibodies and humanized hybrid antibodies wherein amino acid sequences of a non-human donor antibody exhibiting a desired antigen-specificity are combined with sequences of a human acceptor antibody.
• the present disclosure further relates to a device for early differentiating whether a subject suffers from cardioembolic ischemic stroke or from non-cardioembolic ischemic stroke in a subject suffering from ischemic stroke, said device comprising:
• the present disclosure further relates to a device for diagnosing atrial fibrillation, in particular, intermittent atrial fibrillation in a subject suspected to suffer from atrial fibrillation, said device comprising:
• the term “device” as used herein relates to a system comprising the aforementioned units operatively linked to each other as to allow the diagnosis according to the methods of the disclosure.
• Preferred detection agents which can be used for the analyzing unit are disclosed elsewhere herein.
• the analyzing unit preferably, comprises said detection agents in immobilized form on a solid support which is to be contacted to the sample comprising the biomarkers the amount of which is to be determined.
• the analyzing unit can also comprise a detector which determines the amount of detection agent which is specifically bound to the biomarker(s). The determined amount can be transmitted to the evaluation unit.
• Said evaluation unit comprises a data processing element, such as a computer, with an implemented algorithm for carrying out a comparison between the determined amount and a suitable reference.
• Suitable references can be derived from samples of subjects to be used for the generation of reference amounts as described elsewhere herein above.
• the diagnostic results may be given as output of parametric diagnostic raw data, preferably, as absolute or relative amounts. It is to be understood that these data may need interpretation by the clinician.
• the output comprises processed diagnostic raw data the interpretation of which does not require a specialized clinician.
• the device of the present disclosure can be used to carry out the aforementioned method of the present disclosure in an automated manner.
• a preferred embodiment of the instant disclosure includes a system for guiding exercise as set forth herein.
• systems include clinical chemistry analyzers, coagulation chemistry analyzers, immunochemistry analyzers, urine analyzers, nucleic acid analyzers, used to detect the result of chemical or biological reactions or to monitor the progress of chemical or biological reactions.
• exemplary systems of the instant disclosure may include Roche ElecsysTM Systems and Cobas® e Immunoassay Analyzers, Abbott ArchitectTM and AxsymTM Analyzers, Siemens CentaurTM and ImmuliteTM Analyzers, and Beckman Coulter UniCelTM and AcessTM Analyzers, or the like.
• Embodiments of the system may include one or more analyzer units utilized for practicing the subject disclosure.
• the analyzer units of the system disclosed herein are in operable communication with the computing device disclosed herein through any of a wired connection, Bluetooth, LANS, or wireless signal, as are known.
• an analyzer unit may comprise a stand-alone apparatus, or module within a larger instrument, which performs one or both of the detection, e.g. qualitative and/or quantitative evaluation of samples for diagnostic purpose.
• an analyzer unit may perform or assist with the pipetting, dosing, mixing of samples and/or reagents.
• An analyzer unit may comprise a reagent holding unit for holding reagents to perform the assays.
• Reagents may be arranged for example in the form of containers or cassettes containing individual reagents or group of reagents, placed in appropriate receptacles or positions within a storage compartment or conveyor. Detection reagents may also be in immobilized form on a solid support which are contacted with the sample. Further, an analyzer unit may include a process and/or detection component which is optimizable for specific analysis.
• an analyzer unit may be configured for optical detection of an analyte, for example a marker, with a sample.
• An exemplary analyzer unit configured for optical detection comprises a device configured for converting electro-magnetic energy into an electrical signal, which includes both single and multi-element or array optical detectors.
• an optical detector is capable of monitoring an optical electro-magnetic signal and providing an electrical outlet signal or response signal relative to a baseline signal indicative of the presence and/or concentration of an analyte in a sample being located in an optical path.
• Such devices may also include, for example, photodiodes, including avalanche photodiodes, phototransistors, photoconductive detectors, linear sensor arrays, CCD detectors, CMOS detectors, including CMOS array detectors, photomultipliers, and photomultiplier arrays.
• an optical detector such as a photodiode or photomultiplier, may contain additional signal conditioning or processing electronics.
• an optical detector may include at least one pre-amplifier, electronic filter, or integrated circuit. Suitable pre-preamplifiers include, for example, integrating, transimpedance, and current gain (current mirror) pre-amplifiers.
• one or more analyzer unit may comprise a light source for emitting light.
• a light source of an analyzer unit may consist of at least one light emitting element (such as a light emitting diode, an electric powered radiation source such as an incandescent lamp, an electroluminescent lamp, a gas discharge lamp, a high-intensity discharge lamp, a laser) for measuring analyte concentrations with a sample being tested or for enabling an energy transfer (for example, through florescent resonance energy transfer or catalyzing an enzyme).
• a light emitting element such as a light emitting diode, an electric powered radiation source such as an incandescent lamp, an electroluminescent lamp, a gas discharge lamp, a high-intensity discharge lamp, a laser
• an analyzer unit of the system may include one or more incubation units (for example, for maintaining a sample or a reagent at a specified temperature or temperature range).
• an analyzer unit may include a thermocycler, include a real-time thermocycler, for subjecting a sample to repeated temperature cycles and monitoring a change in the amount of an amplification product with the sample.
• an analyzer unit of the system disclosed herein may comprise, or be operationally connected to, a reaction vessel or cuvette feeding unit.
• exemplary feeding units include liquid processing units, such as a pipetting unit, to deliver samples and/or reagents to the reaction vessels.
• the pipetting unit may comprise a reusable washable needle, e.g. a steel needle, or disposable pipette tips.
• the analyzer unit may further comprise one or more mixing units, for example a shaker to shake a cuvette comprising a liquid, or a mixing paddle to mix liquids in a cuvette, or reagent container.
• a computing device may be a general purpose computer or a portable computing device, for example. It should also be understood that multiple computing devices may be used together, such as over a network or other methods of transferring data, for performing one or more steps of the methods disclosed herein. Exemplary computing devices include desktop computers, laptop computers, personal data assistants (“PDA”), such as BLACKBERRY brand devices, cellular devices, tablet computers, servers, and the like.
• PDA personal data assistants
• a computing device comprises a processor capable of executing a plurality of instructions (such as a program of software).
• a computing device has access to a memory.
• a memory is a computer readable medium and may comprise a single storage device or multiple storage devices, located either locally with the computing device or accessible to the computing device across a network, for example.
• Computer-readable media may be any available media that can be accessed by the computing device and includes both volatile and non-volatile media. Further, computer readable-media may be one or both of removable and non-removable media. By way of example, and not limitation, computer-readable media may comprise computer storage media.
• Exemplary computer storage media includes, but is not limited to, RAM, ROM, EEPROM, flash memory or any other memory technology, CD-ROM, Digital Versatile Disk (DVD) or other optical disk storage, magnetic cassettes, magnetic tape, magnetic disk storage or other magnetic storage devices, or any other medium which can be used for storing a plurality of instructions capable of being accessed by the computing device and executed by the processor of the computing device.
• RAM random access memory
• ROM read only memory
• EEPROM electrically erasable programmable read-only memory
• flash memory any other memory technology
• CD-ROM Compact Disk
• DVD Digital Versatile Disk
• magnetic cassettes magnetic tape
• magnetic disk storage magnetic disk storage devices
• software may include instructions which, when executed by a processor of the computing device, may perform one or more steps of the methods disclosed herein. Some of the instructions may be adapted to produce signals that control operation of other machines and thus may operate through those control signals to transform materials far removed from the computer itself.
• the plurality of instructions may also comprise an algorithm which is generally conceived to be a self-consistent sequence of steps leading to a desired result. These steps are those requiring physical manipulations of physical quantities. Usually, though not necessarily, these quantities take the form of electrical or magnetic pulses or signals capable of being stored, transferred, transformed, combined, compared, and otherwise manipulated. It proves convenient at times, principally for reasons of common usage, to refer to these signals as values, characters, display data, numbers, or the like as a reference to the physical items or manifestations in which such signals are embodied or expressed. It should be borne in mind, however, that all of these and similar terms are to be associated with the appropriate physical quantities and are merely used here as convenient labels applied to these quantities.
• an algorithm for carrying out a comparison between a determined amount of one or more markers disclosed herein, and a suitable reference is embodied and performed by executing the instructions.
• the results may be given as output of parametric diagnostic raw data or as absolute or relative amounts.
• a “diagnosis” may be provided by the computing device of a system disclosed herein based on said comparison of the calculated “amount” to a reference or a threshold.
• a computing device of a system may provide an indicator, in the form of a word, symbol, or numerical value which is indicative of a particular diagnosis.
• the computing device may also have access to an output device.
• exemplary output devices include fax machines, displays, printers, and files, for example.
• a computing device may perform one or more steps of a method disclosed herein, and thereafter provide an output, via an output device, relating to a result, indication, ratio or other factor of the method.
• the present disclosure further encompasses a kit for early differentiating whether a subject suffers from cardioembolic ischemic stroke or from non-cardioembolic ischemic stroke in a subject suffers from ischemic stroke, said kit comprising a detection agent for a cardiac Troponin and a standard (standards) which reflects the reference amount(s) as derived from a sample from a subject known suffer from cardioembolic stroke and/or from a subject known to suffer from non-cardioembolic stroke.
• the present disclosure encompasses a kit for diagnosing atrial fibrillation in a subject suspected to suffer from atrial fibrillation, said kit comprising a detection agent for a cardiac Troponin (and, optionally, for a natriuretic peptide) and a standard (standards) which reflects the reference amount(s) as derived from a sample from a subject known suffer from atrial fibrillation and/or from a subject known not to suffer from atrial fibrillation.
• a detection agent for a cardiac Troponin and, optionally, for a natriuretic peptide
• standard standard which reflects the reference amount(s) as derived from a sample from a subject known suffer from atrial fibrillation and/or from a subject known not to suffer from atrial fibrillation.
• kit refers to a collection of the aforementioned components, preferably, provided in separately or within a single container.
• the container also comprises instructions for carrying out the method of the present disclosure. These instructions may be in the form of a manual or may be provided by a computer program code which is capable of carrying out the comparisons referred to in the methods of the present disclosure and to establish a diagnosis accordingly when implemented on a computer or a data processing device.
• the computer program code may be provided on a data storage medium or device such as a optical storage medium (e.g., a Compact Disc) or directly on a computer or data processing device.
• the kit may, preferably, comprise standards which reflect the reference amounts as described and referred to elsewhere herein in detail.
• the detection agent is, preferably, immobilized on a carrier, and, preferably, a test stripe
• Troponin T was determined using Roche's electrochemiluminescence ELISA sandwich test Elecsys Troponin T hs (high sensitive) STAT (Short Turn Around Time) assay.
• the test employs two monoclonal antibodies specifically directed against human cardiac troponin T.
• the antibodies recognize two epitopes (amino acid position 125-131 and 136-147) located in the central part of the cardiac troponin T protein, which consists of 288 amino acids (analytical sensitivity below 1.0).
• NT-proBNP was determined using Roche's electrochemiluminescence ELISA sandwich test Elecsys proBNP II STAT (Short Turn Around Time) assay. The test employs two monoclonal antibodies which recognize epitopes located in the N-terminal part (1-76) of proBNP (1-108).
• ischemic stroke A total of 255 patients with ischemic stroke (mean age 70 years) were tested for NT pro BNP, trponinT and GDF 15. Transitory ischemic attack was present in 23 patients, minor stroke was diagnosed in 61 patients and major stroke was found in 108 patients. In addition as described above caotoid and transcranial ultrasound as well as electro- and echocardiography were performed and the patients were classified according to the TOAST criteria. Moreover a 7 day HOLTER ECG was performed to identify unnoticed atrial fibrillation on the routine electrocardiogram.
• GDF 15 did not contribute significantly to stroke classification, however sensitive troponin T did and thereby excluding the difficulties of separating cardiac and brain B type natriuretic peptides.
• troponin T was found to be a powerful tool in the identification/separation of causes of stroke. This method can also be used in stroke prevention in combination with B type natriuretic peptides. GDF 15 provided surprisingly little additional information to this important clinical question.
• a 68 year old male is diagnosed with TIA (transient ischmemic attack) based on clinical symptoms and a subsequent MRI.
• His ECG is normal.
• His troponin T is 10.2 pg/ml
• his NT-pro BNP is 520 pg/ml.
• An echocardiogram shown mild left ventricular dysfunction, in the atria there was no thrombus formation.
• the subject diagnosed as cardioembolic stroke after ruling out other possibilities. Because of the intraatrial thrombus formation he receives a Holter ECG for 3 days which reveals paroxysmal atrial fibrillation. He is then places on anticoagulant therapy as he had no contraindications.
• a 72 year old male presents with minor stroke confirmed by MRI after ruling out intracerebral bleeding by CT scan.
• His Troponin T is 4.1 pg/ml and his NT-pro BNP is 245 pg/ml.
• a Carotis ultrasound reveals a 80% stenosis of the right carotis fork.
• ECG and echocardiography are normal, except minor diastolic dysfunction. As he is unlikely to have AF a Holter ECG was not carried out. He is advised to consider revision of the obstructed carotis after more intense evaluation of intra- and extracerebral arteries.
• natriuretic peptides have shown usefulness in detecting candidates for cardioembolic stroke in patients presenting with ischemic stroke. However, as shown here natriuretic peptides may change during the course of stroke limiting their diagnostic potential, this is not the case with troponin T which is not subject to substantial change.
• Atrial fibrillation is more frequent in the elderly population. Since diagnostic methods (Holter ECG and detections methods for resulting atrial thrombi, TEE) are of limited availability patient selection (rule in/rule out) is important. This can be achieved by the determination of troponin T (and NT-pro BNP) and the use of appropriate cut offs.
• troponin T as an important diagnostic method in ischemic stroke as well as in intermittent atrial fibrillation in order to direct further diagnostic methods and treatment schedules

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Engineering & Computer Science (AREA)
• Chemical & Material Sciences (AREA)
• Immunology (AREA)
• Biomedical Technology (AREA)
• Molecular Biology (AREA)
• Hematology (AREA)
• Urology & Nephrology (AREA)
• Pathology (AREA)
• Analytical Chemistry (AREA)
• Proteomics, Peptides & Aminoacids (AREA)
• General Health & Medical Sciences (AREA)
• Physics & Mathematics (AREA)
• Microbiology (AREA)
• Biochemistry (AREA)
• Biotechnology (AREA)
• Food Science & Technology (AREA)
• Medicinal Chemistry (AREA)
• Cell Biology (AREA)
• General Physics & Mathematics (AREA)
• Organic Chemistry (AREA)
• Genetics & Genomics (AREA)
• Zoology (AREA)
• Wood Science & Technology (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Biophysics (AREA)
• Oncology (AREA)
• Hospice & Palliative Care (AREA)
• General Engineering & Computer Science (AREA)
• Neurology (AREA)
• Neurosurgery (AREA)
• Investigating Or Analysing Biological Materials (AREA)
• Peptides Or Proteins (AREA)
• Measurement Of The Respiration, Hearing Ability, Form, And Blood Characteristics Of Living Organisms (AREA)

Priority Applications (3)

Applications Claiming Priority (3)

Related Parent Applications (1)

Related Child Applications (1)

Publications (1)

Family

ID=47049159

Family Applications (4)

Family Applications After (3)

Country Status (13)

Cited By (2)

Families Citing this family (6)

Citations (4)

Family Cites Families (47)

• 2012
  • 2012-10-17 BR BR122021026652-2A patent/BR122021026652B1/pt active IP Right Grant
  • 2012-10-17 AU AU2012324967A patent/AU2012324967B2/en active Active
  • 2012-10-17 ES ES16175468T patent/ES2824110T3/es active Active
  • 2012-10-17 CA CA2846285A patent/CA2846285C/en active Active
  • 2012-10-17 JP JP2014536214A patent/JP6117805B2/ja active Active
  • 2012-10-17 ES ES12775484.4T patent/ES2595028T3/es active Active
  • 2012-10-17 EP EP16175468.4A patent/EP3088900B1/en not_active Revoked
  • 2012-10-17 KR KR1020167019896A patent/KR101950561B1/ko active IP Right Grant
  • 2012-10-17 KR KR1020147010178A patent/KR101643147B1/ko active IP Right Grant
  • 2012-10-17 EP EP12775484.4A patent/EP2769227B1/en active Active
  • 2012-10-17 MX MX2014003496A patent/MX347355B/es active IP Right Grant
  • 2012-10-17 CN CN201280062128.XA patent/CN103998938B/zh active Active
  • 2012-10-17 CN CN201610329765.9A patent/CN105785053B/zh active Active
  • 2012-10-17 BR BR112014007007-5A patent/BR112014007007B1/pt active IP Right Grant
  • 2012-10-17 WO PCT/EP2012/070553 patent/WO2013057135A1/en active Application Filing
  • 2012-10-17 SG SG2014014559A patent/SG2014014559A/en unknown
• 2014
  • 2014-04-14 US US14/251,803 patent/US20140220604A1/en not_active Abandoned
  • 2014-09-15 HK HK14109294.8A patent/HK1196158A1/zh unknown
• 2015
  • 2015-09-21 US US14/859,616 patent/US20160011210A1/en not_active Abandoned
• 2016
  • 2016-10-05 US US15/285,798 patent/US20170023588A1/en not_active Abandoned
  • 2016-11-04 JP JP2016216261A patent/JP6412085B2/ja active Active
• 2018
  • 2018-03-05 US US15/911,695 patent/US11047865B2/en active Active

Patent Citations (4)

Also Published As

Similar Documents

Legal Events